Table 1 Demographics and treatment history of the STS PDX donor patients
PDX model | Gender | Age range at diagnosis (years) | STS subtype | Primary tumor location | Metastatic disease at time of engraftment | Metastatic disease after engraftment | Treatment response (after xenografting) |
|---|---|---|---|---|---|---|---|
UZLX-STS22 | Male | 50–60 | Leiomyosarcoma | Quadriceps muscle | No | Yes | PD under doxorubicin + evofosfamide PD under trabectedin |
UZLX-STS39 | Female | 60–70 | Malignant peripheral nerve sheath tumor | Abdominal wall | No | Yes | Refusal of chemotherapy |
UZLX-STS59 | Male | 50–60 | Myxofibrosarcoma | Adductor muscle | Yes | Yes | PD under doxorubicin PD under ifosfamide PD under pazopanib PD under trabectedin |
UZLX-STS84 | Female | 70–80 | Undifferentiated pleomorphic sarcoma | Adductor muscle | No | Yes | PD under pazopanib |